Clinical Trial Detail

NCT ID NCT01593254
Title Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Bristol-Myers Squibb
Indications

chronic myeloid leukemia

Therapies

Imatinib

Dasatinib

Age Groups: adult

Additional content available in CKB BOOST